Pharmaceutical

Jamieson Wellness Inc. (" Jamieson Wellness " or the " Company ") (TSX: JWEL) announced today that the Company has filed its management information circular (" Circular ") and related materials (together with the Circular, the " Meeting Materials ") for the annual meeting of shareholders (the " Shareholders ") of Jamieson Wellness to be held on May 24, 2022 at 2:00 p.m. (Eastern Daylight Time) virtually via live audio webcast at meetnow.globalMZ4D4RR (the " Meeting ").

The Meeting Materials have been filed under Jamieson's profile on SEDAR at www.sedar.com and are also available on the Company's website at www.jamiesonwellness.com .

The Meeting Materials are being mailed to Shareholders to provide information about the business to be conducted at the Meeting, detailed instructions about how to vote shares and how to attend and participate at the Meeting. The Company encourages Shareholders to review the Meeting Materials before voting their shares.

Similar to last year, to proactively address the public health impact of the COVID-19 outbreak, to mitigate the risks to the health and safety of our communities, Shareholders, employees and other stakeholders, and to comply with any applicable public health restrictions limiting indoor events that may be in effect at the time of the Meeting, the Meeting will be held in a virtual only format.

About Jamieson Wellness

Jamieson Wellness is dedicated to improving the world's health and wellness with its portfolio of innovative natural health brands. Established in 1922, Jamieson is the Company's heritage brand and Canada's #1 consumer health brand. The Company also offers a variety of natural health solutions through its Progressive, Smart Solutions, Iron Vegan and Precision brands. For more information please visit jamiesonwellness.com .

Jamieson Wellness' head office is located at 1 Adelaide Street East Suite 2200, Toronto, Ontario, Canada.

Contact

For questions or assistance with the completion and delivery of proxy materials, please contact Jamieson Wellness' proxy solicitation agent and shareholder communications advisor:

Laurel Hill Advisory Group
1.877.452.7184 toll-free in Canada
+1.416.304.0211 International
assistance@laurelhill.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

JWEL:CA

Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis

Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Pfizer's investigational combination therapy for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis: ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi). Fast Track is a process designed to facilitate the development and expedite the review of new drugs and vaccines intended to treat or prevent serious conditions and address unmet medical need.

The FDA's decision is informed by the results of Pfizer's nonclinical studies and a Phase 2a clinical study of ervogastat/clesacostat, which showed that treatment with ervogastat/clesacostat reduced liver fat with a favorable safety and tolerability profile. These data were recently published in Nature Medicine .

Keep reading... Show less

What is In-Licensing?

When it comes to investing in pharmaceutical companies, looking at pipelines and research and development prospects is important. But in-licensing is also key when examining these stocks.

In fact, in-licensing deals might be the pharmaceutical industry’s preferred mode of business development these days — perhaps even more so than mergers and acquisitions (M&A). These agreements can prove to be very fruitful for companies and their share prices.

The in-licensing strategy is likewise attractive to investors: In-licensing drugs expedites corporate development while also mitigating risk. So let’s clear up some common questions around the strategy.

Keep reading... Show less

Pfizer Launches 'An Accord for a Healthier World' to Improve Health Equity for 1.2 Billion People Living in 45 Lower-Income Countries

  • Pfizer will provide all its current and future patent-protected medicines and vaccines available in the U.S. or EU on a not-for-profit basis to 45 lower-income countries.
  • Rwanda, Ghana, Malawi, Senegal and Uganda are the first five countries to commit to join the Accord. Health officials in these countries will help identify and resolve hurdles beyond supply to inform the roll out in all 45 lower-income countries.
  • Pfizer calls upon global health leaders and organizations to join the Accord, bringing their expertise and resources to close the health equity gap and help create a healthier world for 1.2 billion people.

Pfizer Inc. (NYSE: PFE) today launched ‘An Accord for a Healthier World.' This groundbreaking initiative aims to provide all of Pfizer's patented, high-quality medicines and vaccines available in the U.S. or the European Union on a not-for-profit basis to 1.2 billion people in 45 lower-income countries. The Accord seeks to greatly reduce the health inequities that exist between many lower-income countries and the rest of the world.

"As we learned in the global COVID-19 vaccine rollout, supply is only the first step to helping patients. We will work closely with global health leaders to make improvements in diagnosis, education, infrastructure, storage and more. Only when all the obstacles are overcome can we end healthcare inequities and deliver for all patients," said Pfizer Chairman and Chief Executive Officer Albert Bourla.

Keep reading... Show less

Jamieson Wellness Inc. Announces Voting Results from 2022 Annual Meeting of Shareholders

Jamieson Wellness Inc. (" Jamieson Wellness " or the " Company ") (TSX: JWEL) announced today that each of the nominee directors listed in the management information circular of the Company dated March 9, 2022 was elected as a director of the Company (a " Director ") at the annual meeting (the " Meeting ") of the holders of common shares of the Company (the " Common Shares ") held today. The number of Common Shares voted in person or by proxy for the election of each Director or withheld was as indicated below:

Name of Nominee Votes For % Votes Withheld %
Heather Allen 32,745,924 99.94% 18,860 0.06%
Dr. Louis Aronne 32,746,066 99.94% 18,718 0.06%
Tania Clarke 32,749,501 99.95% 15,283 0.05%
Michael Pilato 32,745,960 99.94% 18,824 0.06%
Timothy Penner 30,285,212 92.43% 2,479,572 7.57%
Catherine Potechin 32,743,648 99.94% 21,136 0.06%
Steve Spooner 32,724,932 99.88% 39,852 0.12%
Mei Ye 32,744,145 99.94% 20,639 0.06%

Final results on all matters voted at the Meeting will be filed with the Canadian securities regulatory authorities and will be available on the Company's SEDAR profile at www.sedar.com .

Keep reading... Show less

Merck Announces Third-Quarter 2022 Dividend

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.69 per share of the company's common stock for the third quarter of 2022. Payment will be made on July 8, 2022 to shareholders of record at the close of business on June 15, 2022.

About Merck

Keep reading... Show less

Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-Class Profile in Ulcerative Colitis

- Analyst call will be held to discuss data today at 4:00 PM Eastern Time

Pfizer Inc. (NYSE: PFE) today announced detailed results from two pivotal studies that make up the ELEVATE UC Phase 3 registrational program evaluating etrasimod, a once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator for the treatment of moderately-to-severely active ulcerative colitis (UC). These data were presented as a late-breaker presentation (abstract number 968a) at Digestive Disease Week (DDW) 2022.

Keep reading... Show less

Latest Press Releases

Related News

×